- TactiFlex Duo combines pulsed-field ablation and radiofrequency energy in one catheter, allowing physicians to use either modality or both during AFib procedures.
- Abbott said the FDA approval was supported by FlexPulse IDE study data showing favorable safety and effectiveness outcomes in patients with paroxysmal AFib.
- The approval is Abbott's fifth major electrophysiology approval in just over a year and expands its pulsed-field ablation portfolio.
Quotes
“TactiFlex Duo provides physicians with greater flexibility during procedures, and when it is combined with the high-resolution 3D visualization available through Abbott's EnSite X mapping system, physicians have a suite of practice-changing tools to confidently treat patients with complex AFib.”
“TactiFlex Duo represents an important advancement as Abbott builds the industry's most comprehensive electrophysiology portfolio.”